explore -WSS

explore

author：knowledge 2025-08-25 06:00:49 - browse：9

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — A newly approved Alzheimer’s drug made by Eisai and Biogen, called Leqembi, aims to clear out amyloid plaques in patients’ brains. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

WASHINGTON — Medicare on Monday proposed ending restrictions on how many PET scans patients can receive to detect amyloid plaques in their brains, which will offer physicians more options as they treat patients with a new drug to slow the progression of dementia.

The agency that oversees Medicare had previously restricted coverage to a single scan for patients who participated in clinical studies. Advocates had warned that could cause issues related to a new class of Alzheimer’s drugs designed to clear those plaques.

“We know there is significant interest in the medical community about new treatments that may be effective in slowing the development of Alzheimer’s disease. PET scans are an important part of diagnosis and treatment of Alzheimer’s disease,” Centers for Medicare and Medicaid Administrator Chiquita Brooks-LaSure said in a written statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： Let's speed up science by embracing open access publishing

hotspot

WSS

Cord blood banking comes at a high cost to babies

Change Healthcare can notify patients about the breach, HHS says

An outdated Medicare rule harms dementia patients with anxiety

ASCO Daily Recap: CAR

An outdated Medicare rule harms dementia patients with anxiety

FTC loses bid to block Novant's North Carolina hospital merger

explore

explore

entertainment

Jerome Adams on the need for new antivirals for Covid

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

State Dept. review finds Biden bears some blame for Afghanistan failures

Change Healthcare can notify patients about the breach, HHS says

Activists slam private health insurers over coverage restrictions

Congress needs to close a vaccine

Novavax promises a turnaround & Lilly roils the obesity market

See how much Covid

hotspot

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

Finland to offer bird flu vaccine to select groups of people, a possible global first

Elevance PBM president out as customers face prescription chaos

How CO2 helps viruses stay alive longer in the air

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

STAT wants to know your pick for a great summer read or listen

focus

hotspot

Wikipedia

focus